Lyell Immunopharma (LYEL) Common Equity (2020 - 2026)
Lyell Immunopharma's Common Equity came in at $233.82 million for Q2 2026, down 21.8% from $298.92 million a year earlier and down 14.6% from the prior quarter.
Powered by 
Analysis
Lyell Immunopharma (LYEL) Common Equity (2020 - 2026) Analysis & Trends
At the end of FY2025, Lyell Immunopharma's Common Equity was $248.2 million, down 35.2% from FY2024.
- Common Equity has declined in each of the last four years.
- Going back by year, Common Equity was $382.82 million in FY2024 (-41.5%), $654.95 million in FY2023 (-21.4%), $833.25 million in FY2022 (-10.4%) and $929.79 million in FY2021.
- The Q2 2026 figure represents the lowest quarterly Common Equity since Q1 2021.
- Year-over-year, Common Equity has declined for 17 consecutive quarters, with an average decline of 33.8% over the last eight quarters.
- Across the past five years, year-over-year decline in Common Equity ran from 10.4% in Q4 2022 to 47.2% in Q2 2025.
- Business Quant data shows LYEL's Common Equity at $273.67 million (Q1 2026), $248.2 million (Q4 2025) and $329.12 million (Q3 2025) in the three quarters before Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 84.97 Bn |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | -5.94 Bn |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 41.98 Bn |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | 41.95 Bn |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | 50.37 Bn |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 11.69 Bn |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | 11.83 Bn |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 85.49 Bn |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 20.25 Bn |
| 10 | Lyell Immunopharma | 227.89 Mn | 227.89 Mn | - | 233.82 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 233.82 Mn |
| Mar 31, 2026 | 273.67 Mn |
| Dec 31, 2025 | 248.20 Mn |
| Sep 30, 2025 | 329.12 Mn |
| Jun 30, 2025 | 298.92 Mn |
| Mar 31, 2025 | 336.52 Mn |
| Dec 31, 2024 | 382.82 Mn |
| Sep 30, 2024 | 530.70 Mn |
| Jun 30, 2024 | 566.50 Mn |
| Mar 31, 2024 | 603.16 Mn |
| Dec 31, 2023 | 654.95 Mn |
| Sep 30, 2023 | 697.57 Mn |
| Jun 30, 2023 | 736.86 Mn |
| Mar 31, 2023 | 783.83 Mn |
| Dec 31, 2022 | 833.25 Mn |
| Sep 30, 2022 | 820.03 Mn |
| Jun 30, 2022 | 868.04 Mn |
| Mar 31, 2022 | 881.25 Mn |
| Dec 31, 2021 | 929.79 Mn |
| Sep 30, 2021 | 986.47 Mn |
API Access
Lyell Immunopharma Common Equity API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=common-equity&ticker=LYEL&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "common-equity", "ticker": "LYEL", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=common-equity&ticker=LYEL&period=max&api_key=YOUR_API_KEY");
const data = await res.json();